JP2021531317A - Ｅｔｖ６またはｆｏｘｏ１の発現を調節する中間体ノンコーディングｒｎａ制御因子を含む組成物およびその使用 - Google Patents

Ｅｔｖ６またはｆｏｘｏ１の発現を調節する中間体ノンコーディングｒｎａ制御因子を含む組成物およびその使用 Download PDF

Info

Publication number
JP2021531317A
JP2021531317A JP2021504393A JP2021504393A JP2021531317A JP 2021531317 A JP2021531317 A JP 2021531317A JP 2021504393 A JP2021504393 A JP 2021504393A JP 2021504393 A JP2021504393 A JP 2021504393A JP 2021531317 A JP2021531317 A JP 2021531317A
Authority
JP
Japan
Prior art keywords
expression
etv6
foxo1
composition
coding rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021504393A
Other languages
English (en)
Japanese (ja)
Inventor
ローナ ハリーズ
エヴァ ラトッレ
Original Assignee
ユニバーシティ オブ エクセター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ エクセター filed Critical ユニバーシティ オブ エクセター
Publication of JP2021531317A publication Critical patent/JP2021531317A/ja
Priority to JP2024076795A priority Critical patent/JP2024102292A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
JP2021504393A 2018-07-27 2019-07-29 Ｅｔｖ６またはｆｏｘｏ１の発現を調節する中間体ノンコーディングｒｎａ制御因子を含む組成物およびその使用 Pending JP2021531317A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024076795A JP2024102292A (ja) 2018-07-27 2024-05-09 Ｅｔｖ６またはｆｏｘｏ１の発現を調節する中間体ノンコーディングｒｎａ制御因子を含む組成物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1812334.9 2018-07-27
GBGB1812334.9A GB201812334D0 (en) 2018-07-27 2018-07-27 Compositions and uses thereof
PCT/GB2019/052125 WO2020021291A1 (en) 2018-07-27 2019-07-29 Compositions comprising intermediate non-coding rna regulators modulating the expression of etv6 or foxo1 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024076795A Division JP2024102292A (ja) 2018-07-27 2024-05-09 Ｅｔｖ６またはｆｏｘｏ１の発現を調節する中間体ノンコーディングｒｎａ制御因子を含む組成物およびその使用

Publications (1)

Publication Number Publication Date
JP2021531317A true JP2021531317A (ja) 2021-11-18

Family

ID=63518136

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021504393A Pending JP2021531317A (ja) 2018-07-27 2019-07-29 Ｅｔｖ６またはｆｏｘｏ１の発現を調節する中間体ノンコーディングｒｎａ制御因子を含む組成物およびその使用
JP2024076795A Pending JP2024102292A (ja) 2018-07-27 2024-05-09 Ｅｔｖ６またはｆｏｘｏ１の発現を調節する中間体ノンコーディングｒｎａ制御因子を含む組成物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024076795A Pending JP2024102292A (ja) 2018-07-27 2024-05-09 Ｅｔｖ６またはｆｏｘｏ１の発現を調節する中間体ノンコーディングｒｎａ制御因子を含む組成物およびその使用

Country Status (9)

Country Link
US (1) US20210292765A1 (cg-RX-API-DMAC7.html)
EP (1) EP3830111A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021531317A (cg-RX-API-DMAC7.html)
KR (1) KR20210069626A (cg-RX-API-DMAC7.html)
CN (2) CN120713925A (cg-RX-API-DMAC7.html)
AU (1) AU2019309587B2 (cg-RX-API-DMAC7.html)
CA (1) CA3107700A1 (cg-RX-API-DMAC7.html)
GB (1) GB201812334D0 (cg-RX-API-DMAC7.html)
WO (1) WO2020021291A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11339392B2 (en) 2016-03-02 2022-05-24 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
US12522827B2 (en) 2016-03-02 2026-01-13 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
WO2019159884A1 (ja) * 2018-02-13 2019-08-22 東レ株式会社 認知症の検出のためのキット又はデバイス及び方法
CN115997014A (zh) * 2020-02-14 2023-04-21 小利兰·斯坦福大学董事会 抗呼吸道病毒的泛基因型药剂及其使用方法
CN114159457B (zh) * 2021-12-03 2023-08-22 温州医科大学 一种长链非编码rna、其结合蛋白及应用
CN117757930A (zh) * 2023-11-30 2024-03-26 四川大学华西医院 一种前列腺癌辅助诊断的标志物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006505286A (ja) * 2002-11-05 2006-02-16 ノバルティス・フォルシュングスシュティフトゥング・ツヴァイクニーダーラッスング・フリードリッヒ・ミーシェー・インスティトゥート・フォー・バイオメディカル・リサーチ 細胞増殖のｔｅｌ／ｅｔｖ６−介在阻害
JP2013253031A (ja) * 2012-06-06 2013-12-19 Nissei Bio Kk 抗老化関連遺伝子転写促進剤
WO2017192662A2 (en) * 2016-05-03 2017-11-09 Institute For Systems Biology Methods for identifying treatment targets based on multiomics data

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090156523A1 (en) * 2005-07-11 2009-06-18 Irm Llc Methods and compositions for modulating foxo1 activity and insulin signaling

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006505286A (ja) * 2002-11-05 2006-02-16 ノバルティス・フォルシュングスシュティフトゥング・ツヴァイクニーダーラッスング・フリードリッヒ・ミーシェー・インスティトゥート・フォー・バイオメディカル・リサーチ 細胞増殖のｔｅｌ／ｅｔｖ６−介在阻害
JP2013253031A (ja) * 2012-06-06 2013-12-19 Nissei Bio Kk 抗老化関連遺伝子転写促進剤
WO2017192662A2 (en) * 2016-05-03 2017-11-09 Institute For Systems Biology Methods for identifying treatment targets based on multiomics data

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KLOET D. E. ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1813(11), JPN6023021809, 2011, pages 1926 - 1937, ISSN: 0005071217 *
MCLOUGHLIN H. ET AL., HUMAN MOLECULAR GENETICS, vol. 23, no. 10, JPN6023021810, 2014, pages 2593 - 2603, ISSN: 0005373801 *
TIA N. ET AL., GENE, vol. 648, JPN6023021811, 4 February 2018 (2018-02-04), pages 97 - 105, ISSN: 0005071216 *

Also Published As

Publication number Publication date
EP3830111A1 (en) 2021-06-09
US20210292765A1 (en) 2021-09-23
KR20210069626A (ko) 2021-06-11
WO2020021291A1 (en) 2020-01-30
CN120713925A (zh) 2025-09-30
JP2024102292A (ja) 2024-07-30
CN113166214A (zh) 2021-07-23
AU2019309587B2 (en) 2024-09-19
CA3107700A1 (en) 2020-01-30
AU2019309587A1 (en) 2021-02-18
GB201812334D0 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
Dai et al. Downregulation of circular RNA HECTD1 induces neuroprotection against ischemic stroke through the microRNA-133b/TRAF3 pathway
Zhao et al. SNHG12 promotes angiogenesis following ischemic stroke via regulating miR-150/VEGF pathway
Tao et al. Crucial role of miR-433 in regulating cardiac fibrosis
AU2019309587B2 (en) Compositions comprising intermediate non-coding RNA regulators modulating the expression of ETV6 or FOXO1 and uses thereof
Hu et al. MicroRNA-29 induces cellular senescence in aging muscle through multiple signaling pathways
Shi et al. MiR-145 ameliorates neuropathic pain via inhibiting inflammatory responses and mTOR signaling pathway by targeting Akt3 in a rat model
Latorre et al. FOXO1 and ETV6 genes may represent novel regulators of splicing factor expression in cellular senescence
Xu et al. MiR-155 contributes to Th17 cells differentiation in dextran sulfate sodium (DSS)-induced colitis mice via Jarid2
Du et al. Decorin inhibits angiogenic potential of choroid-retinal endothelial cells by downregulating hypoxia-induced Met, Rac1, HIF-1α and VEGF expression in cocultured retinal pigment epithelial cells
Yang et al. Suppression of TRPM7 Inhibited Hypoxia‐Induced Migration and Invasion of Androgen‐Independent Prostate Cancer Cells by Enhancing RACK1‐Mediated Degradation of HIF‐1α
US20180044672A1 (en) Pericyte Long Non-Coding RNAs
Liu et al. BMP4 reverses multidrug resistance through modulation of BCL-2 and GDNF in glioblastoma
EP2673363B1 (en) Treatment of angiogenesis disorders
KR20230117118A (ko) 건강-수명을 연장하고 연령-관련 질환을 치료하기 위한 방법
Jensen et al. Targeting TNFα produced by astrocytes expressing amyotrophic lateral sclerosis‐linked mutant fused in sarcoma prevents neurodegeneration and motor dysfunction in mice
Sah et al. Ectonucleotide pyrophosphatase 2 (ENPP2) plays a crucial role in myogenic differentiation through the regulation by WNT/β-Catenin signaling
Nguyen et al. Estrogen‐Related Receptor Alpha Promotes Skeletal Muscle Regeneration and Mitigates Muscular Dystrophy
Zhang et al. miR-212 promotes renal interstitial fibrosis by inhibiting hypoxia-inducible factor 1-α inhibitor
US20190241894A1 (en) Molecular re-engineering of excitation-inhibition balance in memory circuits
Kawai et al. Prevention of skeletal muscle atrophy in vitro using anti-ubiquitination oligopeptide carried by atelocollagen
Yu et al. GLIDR promotes the progression of glioma by regulating the miR-4677-3p/MAGI2 axis
US20220125822A1 (en) Treatment Methods for Fibrosis Targeting SMOC2
Zhang et al. SIX1 induced HULC modulates neuropathic pain and Schwann cell oxidative stress after sciatic nerve injury
US20200181649A1 (en) Hybrid formulation of responsive polymeric nanocarriers for therapeutic and diagnostic delivery
US20210261966A1 (en) TREATMENT OF CARDIOMYOPATHY THROUGH MODULATION OF HYPOXIA-INDUCED eRNA ACTIVITY

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220524

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231102

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240509

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240522

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240726